K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.
Asati V, Mahapatra DK, Bharti SK.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2016.09.049 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för BMS-214662. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
21 träffarQuantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients.
Balabanov S, Evans CA, Abraham SA, Pellicano F, Copland M, Walker MJ, Whetton AD, Holyoake TL.
Proteomics · research support, non-u.s. gov't; journal article · DOI 10.1002/pmic.201200022The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.
Pellicano F, Simara P, Sinclair A, Helgason GV, Copland M, Grant S, Holyoake TL.
Leukemia · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/leu.2011.67BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.
Pellicano F, Copland M, Jorgensen HG, Mountford J, Leber B, Holyoake TL.
Blood · research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2009-05-219550Ethyl methanesulphonate in a parenteral formulation of BMS-214662 mesylate, a selective farnesyltransferase inhibitor: formation and rate of hydrolysis.
Nassar MN, Cucolo M, Miller SA.
Pharm Dev Technol · journal article · DOI 10.3109/10837450902980262BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, Weinmann R, Holyoake TL.
Blood · research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2007-09-112573Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG, Holyoake TL.
Biochem Soc Trans · review; journal article · DOI 10.1042/bst0351347Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
Bailey HH, Alberti DB, Thomas JP, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G.
Clin Cancer Res · clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-07-0158Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Eder JP, Ryan DP, Appleman L, Zhu AX, Puchalski T, He X, Sonnichsen DS, Cooper M, Wright J, Clark JW, Supko JG.
Cancer Chemother Pharmacol · clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1007/s00280-005-0134-0Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors.
Papadimitrakopoulou V, Agelaki S, Tran HT, Kies M, Gagel R, Zinner R, Kim E, Ayers G, Wright J, Khuri F.
Clin Cancer Res · clinical trial; research support, u.s. gov't, p.h.s.; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-04-1659A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Erlichman C, Peethambaram P, Pitot HC, Hanson LJ, Reid JM, Furth A, Cheng S, Martell RE, Kaufmann SH, Adjei AA.
Clin Cancer Res · clinical trial; research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-04-1769Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.
Gómez-Benito M, Marzo I, Anel A, Naval J.
Mol Pharmacol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1124/mol.104.007021Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H.
J Clin Oncol · clinical trial; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1200/jco.2005.09.005Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
Tabernero J, Rojo F, Marimón I, Voi M, Albanell J, Guix M, Vázquez F, Carulla J, Cooper M, Andreu J, Van Vreckem A, Bellmunt J, Manne V, Manning JA, Garrido C, Felip E, Del Campo JM, García M, Valverde S, Baselga J.
J Clin Oncol · clinical trial; clinical trial, phase i; journal article · DOI 10.1200/jco.2005.00.398Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
Marzo I, Pérez-Galán P, Giraldo P, López-Royuela N, Gómez-Benito M, Larrad L, Lasierra P, Rubio-Félix D, Anel A, Naval J.
Leukemia · research support, non-u.s. gov't; journal article · DOI 10.1038/sj.leu.2403469Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
Reid TS, Beese LS.
Biochemistry · comparative study; research support, u.s. gov't, p.h.s.; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1021/bi049723bPhase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Ryan DP, Eder JP, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, Clark JW.
Clin Cancer Res · clinical trial; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-0980-3A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors.
Mackay HJ, Hoekstra R, Eskens FA, Loos WJ, Crawford D, Voi M, Van Vreckem A, Evans TR, Verweij J.
Clin Cancer Res · clinical trial; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-03-0327BMS-214662 (Bristol-Myers Squibb).
Johnston SR.
IDrugs · review; journal articlePreclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
Rose WC, Lee FY, Fairchild CR, Lynch M, Monticello T, Kramer RA, Manne V.
Cancer Res · journal articleDiscovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
Hunt JT, Ding CZ, Batorsky R, Bednarz M, Bhide R, Cho Y, Chong S, Chao S, Gullo-Brown J, Guo P, Kim SH, Lee FY, Leftheris K, Miller A, Mitt T, Patel M, Penhallow BA, Ricca C, Rose WC, Schmidt R, Slusarchyk WA, Vite G, Manne V.
J Med Chem · journal article · DOI 10.1021/jm000248z